Healthcare Industry News: AGA Medical
News Release - September 6, 2006
AGA Medical´s patent litigation against OcclutechSept 6, 2006--(HSMN NewsFeed)--Occlutech, a developer of innovative implants for the treatment of structural heart disease such as PFO and ASD today responded to litigation recently initiated by its US competitor AGA Medical. Despite being months away from a commercial launch, AGA has issued a writ against Occlutech in a patent lawsuit, alleging infringement of its German patent.
Occlutech has spent the past few years developing unique technology for the treatment of structural heart disease supported by strong intellectual property. The ongoing clinical trials are proving the strength and superiority of Occlutech´s technology for treating PFO and are expected to lead to CE approval during the first half of 2007.
In a statement issued by Tor Peters, Chairman of Occlutech International AB, he strongly disputes the legitimacy and validity of AGA´s patent infringement claim.
"This looks like a desperate move by AGA in trying to stop relevant innovation. We are very comfortable with our technology and look forward to having Occlutech´s IP position validated in court as soon as possible. Although similar in appearance and ease of handling, the devices differ in several important aspects. Differences include Occlutech´s use of an innovative and distinctive braiding technology, which avoids the use of clamps at the opposing ends of a PFO or ASD occluding device. This significantly improves both safety and performance while reducing the amount of material implanted."
Occlutech´s technology is protected by granted German patent DE 103 38 702 and several other patent applications pending internationally.
Occlutech International AB intends to become a leading global supplier of products for the treatment of structural heart disease. Occlutech maintains R&D and manufacturing facilities in several countries and is currently preparing for the commercial launch of its ranges of PFO and ASD occluders.
The PFO market is expected to see exceptional growth in coming years. Occlutech maintains an extensive pipeline of innovative development projects for the future and is currently active setting up distributorships on international markets.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.